Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | HPGD | P15428 | 7/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21629522 | 1.00 | RAB9A (0.68) | RAB9AALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL21629511 | 1.00 | RAB9A (0.68) | RAB9AALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL21629546 | 1.00 | RAB9A (0.68) | RAB9AALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL30056082 | 0.95 | RAB9A (0.62) | RAB9AALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL21629603 | 0.93 | RAB9A (0.73) | RAB9AALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL21629650 | 0.92 | RAB9A (0.65) | RAB9AALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL21629559 | 0.92 | RAB9A (0.65) | RAB9AALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL21629635 | 0.92 | RAB9A (0.65) | RAB9AALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL21629551 | 0.92 | RAB9A (0.64) | RAB9AALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL21629550 | 0.92 | RAB9A (0.64) | RAB9AALDH1A1HPGDKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252454-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2024-08-01 | — | — | US | claimed |
| EP-4333822-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | Lead Discovery Center GmbH (DE) | 2024-03-13 | — | — | EP | claimed |
| WO-2022233782-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-10 | — | — | WO | claimed |
| US-10703735-B2 | 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | LEAD DISCOVERY CENTER GMBH (DE) | 2020-07-07 | — | — | US | claimed |
| US-20200031794-A1 | 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2020-01-30 | — | — | US | claimed |
| EP-3598972-A1 | 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | Lead Discovery Center GmbH (DE) | 2020-01-29 | — | — | EP | claimed |
| US-20240252454-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2024-08-01 | — | — | US | disclosed |
| EP-4333822-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | Lead Discovery Center GmbH (DE) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022233782-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-10 | — | — | WO | disclosed |
| US-10703735-B2 | 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | LEAD DISCOVERY CENTER GMBH (DE) | 2020-07-07 | — | — | US | disclosed |
| US-10703735-B2 | 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | LEAD DISCOVERY CENTER GMBH (DE) | 2020-07-07 | — | — | US | disclosed |
| US-20200031794-A1 | 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2020-01-30 | — | — | US | disclosed |
| US-20200031794-A1 | 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2020-01-30 | — | — | US | disclosed |
| EP-3598972-A1 | 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | Lead Discovery Center GmbH (DE) | 2020-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252454-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | TFAM, POLRMT, TUFM | RAB9A 4733/4885ALDH1A1 3415/4885HPGD 1853/4885 |
| US-20200031794-A1 | 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | POLRMT, COX4I1, UQCRC2 | RAB9A 4170/4885ALDH1A1 1344/4885HPGD 1377/4885 |
| US-10703735-B2 | 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | POLRMT, COX4I1, UQCRC2 | RAB9A 4170/4885ALDH1A1 1344/4885HPGD 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.